510 likes | 768 Views
Drugs affecting the parasympathetic and somatic nervous system. Nervous System. CNS. PNS. Brain Spinal Cord. Autonomic NS. Somatic NS. Sympathetic. Parasympathetic. Drugs and Cholinergic Synapses. PRESYNAPTIC. POSTSYNAPTIC. Choline uptake and Ach synthesis. Metabolic Removal.
E N D
Drugs affecting the parasympathetic and somatic nervous system
Nervous System CNS PNS Brain Spinal Cord Autonomic NS Somatic NS Sympathetic Parasympathetic
PRESYNAPTIC POSTSYNAPTIC Choline uptake and Ach synthesis Metabolic Removal Choline AChE S & S ACh Action ACh M / N Receptor Binding
PRESYNAPTIC POSTSYNAPTIC Choline uptake and Ach synthesis Metabolic Removal Choline AChE S & S ACh Action ACh M / N Receptor Binding
PRESYNAPTIC POSTSYNAPTIC Choline uptake and Ach synthesis Metabolic Removal Choline AChE S & S ACh Action ACh M / N Receptor Binding
PRESYNAPTIC POSTSYNAPTIC Choline uptake and Ach synthesis Metabolic Removal Choline AChE S & S ACh Action ACh M / N Receptor Binding
PRESYNAPTIC POSTSYNAPTIC Choline uptake and Ach synthesis Metabolic Removal Choline AChE S & S ACh Action ACh M / N Receptor Binding
Cholinomimetic Drugs Direct Acting Indirect Acting Receptor Agonists Cholinesterase Inhibitors ●choline esters ● carbamates ●organophosphates ● alkaloids
ACh nicotinic muscarinic (N) (M) Cholinergic Receptors
MUSCARINIC RECEPTOR SUBTYPES • M1: NEURONAL CNS AND ANS PRESYNAPTIC • M2: CARDIAC • M3: SMOOTH MUSCLE AND GLANDULAR • M3: VASCULAR ENDOTHELIUM • (NON-INNERVATED)
CNS Muscarinic Agonists/Antagonists C ACh M N ACh T ACh 1 NE N L NE ACh 1 N SG M ACh 2 S ACh SM N
Nicotinic Agonists/ Antagonists CNS C ACh M N ACh T ACh 1 NE N L NE ACh 1 N SG M ACh 2 S ACh SM N
EFFECTS OF STIMULATING MUSCARINIC RECEPTORS (SLUDE) SITEEFFECT HEART BRADYCARDIA VASCULATURE VASODILATION BRONCHOSPASM AIRWAYS IRIS MIOSIS BLADDER INCREASED URINATION GI TRACT INCREASED GI MOTILITY INCREASED SALIVATION SALIVARY GLANDS INCREASED TEARS LACRIMAL GLANDS SWEAT GLANDS INCREASED SWEATNG
MUSCARINIC AGONISTS ACh - no clinical use • Choline Esters bethanechol– muscarinic agonist • effects mostly on GI and urinary system when administered p.o. or s.c. • used to prevent urinary retention •adverse effects – overstimulation of muscarinic receptors • carbachol – muscarinic and nicotinic agonist • used to produce miosis during ocular surgery
MUSCARINIC AGONISTS: Alkaloids pilocarpine – muscarinic agonist • •No nicotinic effects •Used topically to treat glaucoma • Orally for the treatment of xerostomia • •Somewhat selective for salivary glands • Used for Sjorgren’s Syndrome Adverse Effects: ‘over stimulation’ of muscarinic receptors
Glaucoma Closed (or narrow)-angle glaucoma: The drainage angle of the eye becomes physically blocked by a narrow angle, preventing drainage of aqueous humour slowly or suddenly. Chronic open-angle glaucoma (most common): The drainage angle of the eye becomes less efficient with time causing inefficient drainage of aqueous humour and increased pressure within the eye. Gradually produces optic nerve damage.
Management of Glaucoma: Lower intraocular pressure Treatment – Increase outflow of aqueous humour • mitotic agents (parasympathomimetics; e.g. pilocarpine) • Cholinesterase Inhibitors (physostigmine) • Other: prostaglandin analogs (latanoprost), alpha-2 agonists (brimonidine) Treatment – Decrease ciliary body production of aqueous humour • Carbonic anydrase inhibitors; e.g. acetazolamide) • Topical beta-blockers (timolol, levobunolol)
Antimuscarinic Drugs ●atropine Natural Alkaloids ● scopolamine ● ipratropium (quaternary) Semi-synthetic Derivatives ● tiotropium (quaternary; 24h duration) ●glycopyrrolate ●oxybutynin
CNS Muscarinic Antagonists ACh C X N ACh M T ACh 1 NE N L NE ACh 1 N X SG ACh M 2 S ACh SM N
ANTIMUSCARINIC AGENTS • • ATROPINE BELLADONNA ALKALOIDS • • SCOPOLAMINE TX: USED WHEN A REDUCTION OF PARASYMATHETIC TONE IS DESIRABLE • • Preop to reduce salivations / bronchial secretions • • Reduce intestinal motility • • Prevent vagal stimulation during anesthesia and surgery • Treat overactive bladder • Ophthalmological examinations • Prevent motion sickness • • Treat asthma • • Treat AChE inhibitor poisoning
ATROPINE: OVERVIEW OF TOXIC ACTIONS DRY AS A BONE HOT AS A PISTOL REDAS A BEET BLIND AS A BAT MAD AS A HATTER
ATROPINE: OVERVIEW OF ACTIONS • 0.5 mg: Paradoxical bradycardia; Some dryness of mouth; Inhibition of sweating • 1.0 mg: Increased xerostomia; Thirst; Mild tachycardia; Mild mydriasis • 2.0 mg: Marked tachycardia; Xerostomia; Pupilary dilation; Some blurring of vision and decrease in gastric acid secretion
ATROPINE: OVERVIEW OF ACTIONS • 5.0 mg: Difficulty in speaking, swallowing and urination; Decreased intestinal motility; Restlessness; Headache; Dry hot skin • 10 mg & UP: Rapid and weak pulse; Fixed, maximally dilated pupils; Blurred vision; Ataxia; Excitement; Hallucinations and delirium; Coma.
ATROPINE OVERDOSE: ANTIDOTE - Physostigmine Choline AChE ACh S & S Action ACh M Atropine
ATROPINE OVERDOSE: ANTIDOTE - Physostigmine Physostigmine Choline X AChE ACh S & S ACh Action M Atropine
CHOLINESTERASE (AChE) INHIBITORS AGENTS USED TO ENHANCE TRANSMISSION AT CHOLINERGIC JUNCTIONS •Short-acting (noncovalent inhibitors) •Medium-duration (‘reversible’ carbamate inhibitors) •Irreversible (organophosphates)
Cholinesterase Inhibitors CNS C ACh M N ACh T ACh 1 NE N L NE ACh 1 N SG ACh M 2 S ACh SM N
Cholinesterase Inhibitors - Action Ach - normally removed from synapse via AChE AChE Inhibitor X AChE ACh S & S ACh Action M / N Receptor Binding
Cholinesterase Inhibitors (reversible) Carbamates; BIND TO THE ESTERATIC SITE OF AChE • PHYSOSTIGMINE - READILY PENETRATES CNS - DRUG OF CHOICE TO TREAT POISONING WITH ATROPINIC AGENTS • NEOSTIGMINE and PYRIDOSTIGMINE - DO NOT PENETRATE CNS - USED TO TREAT ALZHEIMER’S AND DEMENTIA - USED TO TREAT MYASTHENIA GRAVIS - NEOSTIGMINE USED AS ANTIDOTE FOR OVERDOSE OF “CURARE-LIKE” DRUGS - USED TO TREAT GLAUCOMA
Cholinesterase Inhibitors • EDROPHONIUM - Very short acting - Diagnostic agent used to test for myasthenia gravis
CHOLINESTERASE INHIBITORS: ACUTE TOXICITY SYMPTOMS DUE TO EXCESS OF ACh AT SYNAPSE • MUSCARINIC RECEPTORS - SLUDE • NICOTINIC RECEPTORS - FASCICULATION, MUSCLE CRAMPS, WEAKNESS, RESPIRATORY PARALYSIS
Cholinesterase Inhibitors - Action and Reversal Ach - normally removed from synapse via AChE AChE Inhibitor X AChE ACh ACh Action M / N Receptor Binding
Antidote for Overdose of Carbamate Cholinesterase Inhibitors: Atropine AChE Inhibitor X AChE ACh ACh Action M / N Atropine
Cholinesterase Inhibitors • ORGANOPHOSPHATES: IRREVERSIBLY PHOSPHORYLATE • SERINE HYDROXYL AT ACTIVE SITE OF AChE INSECTICIDES • • Malathion, Parathion, Diazinon NERVE GASES • Sarin, Soman, Tabun
Antidote for Overdose of Organophosphate Cholinesterase Inhibitors: 2-Pralidoxime (2-PAM)
GANGLIONIC BLOCKING AGENTS • TRIMETHAPHAN • - Used to produce controlled hypotension • HEXAMETHONIUM GANGLIONIC STIMULATING AGENTS • NICOTINE
NEUROMUSCULAR (NMJ) BLOCKING AGENTS
CNS NMJ Blocking Agents ACh C M N ACh T ACh 1 NE N L NE ACh 1 N SG ACh M 2 S ACh SM N
NMJ Blocking Agents NMJ BLOCKING AGENTS USED IN SURGERY TO PROMOTE SKELETAL MUSCLE RELAXATION • - Intubation • - Maintain controlled ventilation • - Paralysis of skeletal muscle in area • of surgery
NMJ BLOCKING DRUGS NONDEPOLARIZING (competative) DEPOLARIZING (non-competative) • •SUCCINYLCHOLINE Long Duration • TUBOCURARINE Intermediate Duration • PANCURONIUM Short Duration • MIVACURIUM
Nondepolarizing NMJ Blocking Agents: Mechanism of Action AChE SM ACh SM paralysis ACh N Tubocurarine
Antidote for Overdose of nondepolarizing NMJ Blocking Agents: Neostigmine Neostigmine X AChE recovery from SM paralysis SM ACh ACh N Tubocurarine
Depolarizing NMJ Blocking Agents: Mechanism of Action Caution: Succinylcholine may produce hyperkalemia AChE SM ACh SM paralysis ACh N Succinylcholine
Antidote for overdose of Succinylcholine: ‘no pharmacological approach’; ventilation AChE recovery from SM paralysis SM ACh ACh N Succinylcholine butyrlcholinesterase